Currently, 2 types of antibodies targeting IL-5 and IL-5Rα have been developed for the treatment of BA: anti-IL-5 antibodies (mepolizumab and reslizumab) and anti-IL-5Rα antibodies (benralizumab). This evidence concerns the gene IL5 and breast angiosarcoma.